다낭성난소증후군 치료 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 수술별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)
Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Surgery, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
상품코드
:
1750634
리서치사
:
Grand View Research
발행일
:
2025년 05월
페이지 정보
:
영문 100 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
다낭성난소증후군 치료 시장 성장과 동향:
Grand View Research, Inc.의 최신 보고서에 따르면, 세계 다낭성난소증후군 치료제 시장 규모는 2030년까지 69억 9,000만 달러에 달할 것으로 예상되며, 2025-2030년 6.6%의 CAGR을 기록할 것으로 추정됩니다. 미국 질병통제예방센터(CDC)에 따르면 다낭성난소증후군(PCOS)은 여성 불임의 가장 흔한 원인입니다. 미국에서는 가임기 여성의 약 6%-12%가 PCOS를 앓고 있습니다. 또한, 이 질환이 진행되면 대사 이상이 발생하여 치료가 늦어지면 제2형 당뇨병으로 발전할 수 있습니다. 이 질환의 중증도는 환자의 자궁체암과 자궁내막암 발병 위험을 높입니다. 따라서 조기 진단과 효과적인 치료가 회복을 위해 중요합니다.
현재 이 질환에 대한 특효약은 시판되고 있지 않습니다. 따라서 증상을 치료하는 것이 치료의 일차적인 목적입니다. 이 증후군에 수반되는 다양한 증상으로 인해 다양한 약물 계열/조합이 치료에 사용됩니다. 따라서 시장 선두주자들은 이 질환의 근본 원인을 치료할 수 있는 특정 약물/치료법 개발에 집중하고 있습니다. 아스트라제네카는 이러한 약물 개발에 참여하고 있는 선두주자 중 하나입니다.
다낭성난소증후군 치료 시장 보고서 하이라이트
약제 클래스별로는 인슐린 저항성 개선제가 2024년 36.0%의 점유율을 차지하며 시장을 주도했습니다.
수술별로는 난소 쐐기 절제술이 예측 기간 동안 상당한 CAGR로 성장할 것으로 예상됩니다.
판매 채널별로는 온라인 공급자 부문이 예측 기간 동안 가장 빠른 CAGR을 기록할 것으로 예상됩니다.
아시아태평양 다낭성난소증후군 치료 시장은 예측 기간 동안 가장 빠른 CAGR을 기록할 것으로 예상됩니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 다낭성난소증후군 치료 시장 변수, 동향, 범위
시장 소개/계통 전망
시장 규모와 성장 전망
시장 역학
시장 성장 촉진요인 분석
시장 성장 억제요인 분석
다낭성난소증후군 치료 시장 분석 툴
제4장 다낭성난소증후군 치료 시장 : 약물 종류 추정·동향 분석
부문 대시보드
다낭성난소증후군 치료 시장 : 약물 종류 변동 분석, 2024년 및 2030년
경구 피임약
항안드로겐
인슐린 저항성 개선제
항우울제
비만 예방
제5장 다낭성난소증후군 치료 시장 : 수술 추정·동향 분석
부문 대시보드
다낭성난소증후군 치료 시장 : 수술 변동 분석, 2024년 및 2030년
난소 설상 절제술
복강경 난소 천공술
제6장 다낭성난소증후군 치료 시장 : 유통 채널 추정·동향 분석
부문 대시보드
다낭성난소증후군 치료 시장 : 유통 채널 변동 분석, 2024년 및 2030년
원내 약국
드럭스토어와 소매 약국
온라인 프로바이더
제7장 다낭성난소증후군 치료 시장 : 지역 추정·동향 분석
다낭성난소증후군 치료 시장 점유율 : 지역별, 2024년 및 2030년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
제8장 경쟁 구도
주요 시장 진입 기업의 최근 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 개요
AstraZeneca
Bayer AG
Merck KGaA.
Abbott
Pfizer, Inc
Sanofi
Bristol Myers Squibb Company
Teva Pharmaceutical Industries Ltd
Novartis AG
Ferring BV
ksm
영문 목차
Polycystic Ovarian Syndrome Treatment Market Growth & Trends:
The global polycystic ovarian syndrome treatment market size is estimated to reach USD 6.99 billion by 2030, registering a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery.
Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.
Polycystic Ovarian Syndrome Treatment Market Report Highlights:
Based on drug class, the insulin-sensitizing agents dominated the market and accounted for a share of 36.0% in 2024.
By surgery, the ovarian wedge resection segment is expected to grow at a significant CAGR over the forecast period.
Based on the distribution channel, the online providers segment is expected to register the fastest CAGR during the forecast period.
Asia Pacific's polycystic ovarian syndrome treatment market is estimated to register the fastest CAGR over the forecast period.
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Polycystic Ovarian Syndrome Treatment Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Polycystic Ovarian Syndrome Treatment Market Analysis Tools
3.4.1. Porter's Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Polycystic Ovarian Syndrome Treatment Market: Drug Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Polycystic Ovarian Syndrome Treatment Market:, Drug Class Movement Analysis, 2024 & 2030 (USD Billion)
4.3. Oral Contraceptives
4.3.1. Oral Contraceptives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4. Antiandrogens
4.4.1. Antiandrogens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.5. Insulin-sensitizing Agent
4.5.1. Insulin-sensitizing Agent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.6. Antidepressant
4.6.1. Antidepressant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.7. Anti-obesity
4.7.1. Anti-obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 5. Polycystic Ovarian Syndrome Treatment Market: Surgery Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Polycystic Ovarian Syndrome Treatment Market: Surgery Movement Analysis, 2024 & 2030 (USD Billion)
5.3. Ovarian Wedge Resection
5.3.1. Ovarian Wedge Resection Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.4. Laparoscopic Ovarian Drilling
5.4.1. Laparoscopic Ovarian Drilling Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 6. Polycystic Ovarian Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Polycystic Ovarian Syndrome Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Billion)
6.3. Hospital Pharmacy
6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.4. Drug Store & Retail Pharmacy
6.4.1. Drug Store & Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5. Online Providers
6.5.1. Online Providers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 7. Polycystic Ovarian Syndrome Treatment Market: Regional Estimates & Trend Analysis
7.1. Polycystic Ovarian Syndrome Treatment Market Share, By Region, 2024 & 2030 (USD Billion)
7.2. North America
7.2.1. North America Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.2. U.S.
7.2.3. U.S. Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.4. Canada
7.2.4.1. Canada Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.5. Mexico
7.2.5.1. Mexico Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3. Europe
7.3.1. Europe Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.2. UK
7.3.2.1. UK Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.3. Germany
7.3.3.1. Germany Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.4. France
7.3.4.1. France Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4. Asia Pacific
7.4.1. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.2. China
7.4.2.1. China Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.3. Japan
7.4.3.1. Japan Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.4. India
7.4.4.1. India Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.5. South Korea
7.4.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.6. Australia
7.4.6.1. Australia Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Latin America
7.5.1. Latin America Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.2. Brazil
7.5.2.1. Brazil Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.3. UAE
7.6.3.1. UAE Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.4. South Africa
7.6.4.1. South Africa Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. AstraZeneca
8.4.1.1. Participant's Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Bayer AG
8.4.2.1. Participant's Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Merck KGaA.
8.4.3.1. Participant's Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Abbott
8.4.4.1. Participant's Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Pfizer, Inc
8.4.5.1. Participant's Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Sanofi
8.4.6.1. Participant's Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Bristol Myers Squibb Company
8.4.7.1. Participant's Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Teva Pharmaceutical Industries Ltd
8.4.8.1. Participant's Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Novartis AG
8.4.9.1. Participant's Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Ferring B.V.
8.4.10.1. Participant's Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
관련자료
